Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Nov
11
Today In Oncology
CTCL Denileukin Diftitox May Improve HRQoL
Anbenitamab/HB1801 vs THP in HER2-Positive Advanced Breast Cancer
KEYNOTE-867 Immunotherapy Should Not Be Combined With SBRT in Unresected Early-Stage NSCLC
FDA Approves Pimicotinib for Symptomatic TGCT
HERON-Lung01 HER3-Directed ADC Prolongs PFS in EGFR-Mutated Advanced NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo